Am J Psychiatry 158:1517-1519, September 2001
© 2001 American Psychiatric Association
Randomized Study of the Dopamine Receptor Agonist Piribedil in the Treatment of Mild Cognitive Impairment
Dindagur Nagaraja, D.M.(Neuro.), D.P.M., M.A.M.S., and
Sivaramakrishnan Jayashree, M.D.
OBJECTIVE: Age-related decrease in dopamine D2 receptors is associated with cognitive decline in healthy elderly individuals. This study was an investigation of whether the dopamine receptor agonist piribedil improves global cognitive function in patients with mild cognitive impairment. METHOD: In a 90-day randomized double-blind study, treatment with piribedil was compared to placebo in 60 patients with clinically diagnosed mild cognitive impairment and a Mini-Mental State Examination (MMSE) score of 21 to 25. The primary outcome was change in MMSE score. RESULTS: Of the 30 patients randomly assigned to each treatment group, 19 (63.3%) of those taking piribedil and eight (26.7%) of those treated with placebo had increases in MMSE scores, to 26 or more. The response rate and the mean increase in MMSE scores were significantly greater with piribedil. CONCLUSIONS: Patients with mild cognitive impairment had improvement in global cognitive function when treated with the dopamine receptor agonist piribedil. The results support the role of age-related dopamine decline in cognitive impairment of the elderly.
This article has been cited by other articles:
|
|
|
|
 
S. Vale
Current Management of the Cognitive Dysfunction in Parkinson's Disease: How Far Have We Come?
Experimental Biology and Medicine,
August 1, 2008;
233(8):
941 - 951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Sarkamo, M. Tervaniemi, S. Laitinen, A. Forsblom, S. Soinila, M. Mikkonen, T. Autti, H. M. Silvennoinen, J. Erkkila, M. Laine, et al.
Music listening enhances cognitive recovery and mood after middle cerebral artery stroke
Brain,
March 1, 2008;
131(3):
866 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Turle-Lorenzo, B. Maurin, C. Puma, C. Chezaubernard, P. Morain, C. Baunez, A. Nieoullon, and M. Amalric
The Dopamine Agonist Piribedil with L-DOPA Improves Attentional Dysfunction: Relevance for Parkinson's Disease
J. Pharmacol. Exp. Ther.,
November 1, 2006;
319(2):
914 - 923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gobert, B. Di Cara, L. Cistarelli, and M. J. Millan
Piribedil Enhances Frontocortical and Hippocampal Release of Acetylcholine in Freely Moving Rats by Blockade of alpha 2A-Adrenoceptors: A Dialysis Comparison to Talipexole and Quinelorane in the Absence of Acetylcholinesterase Inhibitors
J. Pharmacol. Exp. Ther.,
April 1, 2003;
305(1):
338 - 346.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. J. Millan, L. Maiofiss, D. Cussac, V. Audinot, J.-A. Boutin, and A. Newman-Tancredi
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes
J. Pharmacol. Exp. Ther.,
November 1, 2002;
303(2):
791 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Newman-Tancredi, D. Cussac, V. Audinot, J.-P. Nicolas, F. De Ceuninck, J.-A. Boutin, and M. J. Millan
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and alpha 1/alpha 2-Adrenoceptor
J. Pharmacol. Exp. Ther.,
November 1, 2002;
303(2):
805 - 814.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
